LivaNova PLC

LivaNova PLC

LIVNNYSE / NASDAQHealthcareSmall cap

$90.73-$1.34 (-1.5%)

Last close · Data as of Nov 20, 2026

Market cap
$4.0B
P/E
-16.7x
EV / EBITDA
-34.4x
Revenue
$1.4B
Net margin
-17.5%
ROCE
11.1%

+69.8% over the last year

LivaNova PLC price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+13.8%
3M
+16.0%
6M
+23.1%
1Y
+69.8%
5Y
+5.4%

52-week range

Day change -$1.34 (-1.5%) from $92 to $91 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LIVN, bought on each weekday since 2021.

News & filings

What LivaNova filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 242 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 10.7% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation.

Read moreShow less

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Sector
Healthcare
Shares outstanding
54.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.0B
P/E
-16.7x
P/B
3.4x
EV / EBITDA
-34.4x
EV / Sales
2.8x
P/S
2.9x
52-week high
$94.54
52-week low
$53.42

Profitability

Operating margin
14.4%
Net margin
-17.5%
EBITDA margin
-8.1%
ROE
-20.2%
ROCE
11.1%
ROIC
-13.6%
ROA
-9.3%
Asset turnover
0.53

Growth

Revenue
$1.4B
Revenue growth, 1Y
10.7%
Revenue CAGR, 3Y
10.8%
Net profit growth, 1Y
-483.5%
Free cash flow
$173.3M

Solvency

Current ratio
1.36
Debt / Equity
0.36
Debt / Assets
0.17
CFO / Net profit
-1.05
Cash / Market cap
15.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$1.4B
Cost of revenue$448.2M
Gross profit$939.9M
Operating expenses$740.5M
Research and development$185.8M
Selling, general and administrative$548.8M
Operating income$199.4M
Interest and other-$420.2M
Pretax income-$220.8M
Tax and other$21.7M
Net income-$242.5M

Revenue and net profit

Revenue grew 10.7% in FY2025; net profit is the dashed line.

LivaNova PLC revenue and net profit by fiscal year
LivaNova PLC revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.0B-$86.2M
FY2023$1.2B$17.5M
FY2024$1.3B$63.2M
FY2025$1.4B-$242.5M

Cash flows

FY2025: $254.3M from operations, $173.3M free after investment (dashed).

LivaNova PLC operating and free cash flow by fiscal year
LivaNova PLC operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$69.9M$43.4M
FY2023$74.9M$39.9M
FY2024$183.0M$135.9M
FY2025$254.3M$173.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.4B+10.7%1Y
EBITDA
-$111.9M-155.2%1Y
Net profit
-$242.5M-483.5%1Y
Cash from operations
$254.3M+39.0%1Y
Free cash flow
$173.3M+27.5%1Y
Revenue CAGR, 3Y
10.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.4B-$111.9M-$242.5M$173.3M-20.2%+10.7%-483.5%

Monthly returns

Month-by-month returns of LIVN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.6B
Liabilities$1.4B
Equity$1.2B
Paid-in capital$2.3B
Retained earnings-$1.1B
Treasury stock$1.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LIVN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. LivaNova PLC (this company)2.8x

Not shown (no positive earnings and no EV / Sales): Celcuity Inc., Erasca, Inc., Edgewise Therapeutics, Inc., Oruka Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
LivaNova PLCLIVNthis company$4.0B-16.7x3.4x-20.2%-34.4x
Amicus Therapeutics, Inc.FOLD$4.5B-167.8x16.6x-9.9%88.8x
Celcuity Inc.CELC$4.5B-25.5x44.8x-176.1%-29.2x
Travere Therapeutics, Inc.TVTX$4.3B-168.1x37.4x-22.2%203.9x
10x Genomics, Inc.TXG$4.3B-97.7x5.3x-5.5%988.3x
Erasca, Inc.ERAS$4.1B-33.1x12.7x-38.3%-32.0x
Edgewise Therapeutics, Inc.EWTX$4.0B-23.9x7.7x-32.1%-20.9x
Oruka Therapeutics, Inc.ORKA$3.8B—9.9x-22.5%—
Crinetics Pharmaceuticals, Inc.CRNX$3.7B-7.8x3.7x-46.9%-7.0x
Peer median—-33.1x11.3x-27.3%-7.0x

Year-to-date ROI

LIVN since 1 January, against earlier years.

Historical volatility

LIVN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

LivaNova PLC operating margin by fiscal year
LivaNova PLC operating margin by fiscal year
DateOperating margin
FY20225.2%
FY20231.9%
FY202410.3%
FY202514.4%
LineFY2025
Cost of revenueCost Of Revenue$448.2M
Gross profitGross Profit$939.9M
Operating expensesOperating Expense$740.5M
Research and developmentResearch And Development$185.8M
Selling, general and administrativeSelling General And Administration$548.8M
Other operating expensesOther Operating Expenses$5.9M
Total expensesTotal Expenses$1.2B
Pretax incomePretax Income-$220.8M

Learn while you research

Academy chapters picked for LivaNova PLC and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →